key: cord-0686361-3sajmjtp
authors: Sookaromdee, Pathum; Wiwanitkit, Viroj
title: Correspondence on ‘BNT162b2 vaccine‐associated myo/pericarditis in adolescents’
date: 2022-04-02
journal: Eur J Clin Invest
DOI: 10.1111/eci.13780
sha: 776c77756edda3ac9d323f73e905f0d5e20dc634
doc_id: 686361
cord_uid: 3sajmjtp

nan

Dear Editor, We would like to share ideas on the publication 'BNT162b2 vaccine-associated myo/pericarditis in adolescents: A Stratified Risk-Benefit Analysis.' 1 Krug et al. reported a comprehensive analysis of an original study and concluded that 'Our findings strongly support individualized paediatric COVID-19 vaccination strategies, which weigh protection against severe disease vs. risks of vaccineassociated myo/pericarditis. Research is needed into the nature and implications of this adverse effect and immunization strategies, which reduce harm in this overall low-risk cohort.' 1 We agree that COVID-19 can have negative side effects, with myo/pericarditis being one among them. Krug et al. analyzed data from the Vaccine Adverse Event Reporting System (VAERS) in this investigation. The current investigation looked at comorbidity and clinical history, and other factors. The clinical condition in a COVID-19 vaccine recipient with myo/pericarditis may or may not be related to the vaccine. The affected adolescent's pre-vaccination health/immune status is frequently unknown, and there may be a consequence of an underlying health problem. There is no direct examination of the background disease, according to VAERS. There is also the possibility of a coexisting medical condition. Dengue fever, for example, can occur in a vaccine recipient 2 and cause a heart problem. 3 The VAERS retrospective data may not be able to detect the silent underlying disease or a concomitant medical condition. A history of past infection, for example, cannot rule out previous asymptomatic COVID-19 infection or another silent concomitant medical issue. On the other hand, there might also be an underestimation of myo/pericarditis because the vaccine recipients might not have reported chest pain after the vaccination. Currently, there is no standard investigation on myo/pericarditis after the vaccination. In general, there are limited data on the incidence of myo/pericarditis after vaccination (Table 1) . [4] [5] [6] [7] [8] [9] [10] In the pre-COVID-19 era, the reported incidence of myopericarditis among healthy persons without vaccination was equal to 0.95 cases per 100,000. 4 Focussing on vaccinated persons, an incidence equal to 5.5 per 10,000 was reported in a study on smallpox vaccination. 5 However, those studies did not cover the adolescent group. The specific data on myo/pericarditis in adolescents are limited.

Based on these considerations, the actual incidence of myo/pericarditis following COVID-19 vaccination may be different than what has been found. Given the aforementioned considerations, the exact incidence should be further studied. Most likely, the incidence of myo/pericarditis might be a result of the vaccination. Almost all cases have symptoms and abnormal cardiac biomarkers within 5 days after vaccination. Although there is a low incidence of myo/pericarditis, it is still necessary to recognize for future 'quality of life', which has never been determined yet. In previous reports, there is no longterm complication of myo/pericarditis after smallpox or influenza vaccination. 5, 6 For COVID-19 vaccinationassociated myo/pericarditis, there is no report on the long-term consequence. However, most reported cases of COVID-19 vaccination-associated myo/pericarditis are not severe, and the prognosis is good; hence, there should be no long-term complication. Finally, there are other potential complications of the vaccine, such as effects on the dermatological and hematological system, that may have an additional impact. Nevertheless, the incidence of other important adverse events after COVID-19 vaccination is lower than that of a cardiac problem (for example, the incidence of anaphylaxis is only 0.5 per 100,000 11 ). Based on the available data (Table 1) , the reported incidence of COVID-19 vaccination-associated myo/ pericarditis is significantly lower than the incidence of COVID-19-related myo/pericarditis. In the authors' opinion, the COVID-19 vaccine still has a benefit over risk. It is no doubt that the mass vaccination should continue. Nevertheless, further studies on the efficacy and safety of COVID-19 vaccination are still required. 

BNT162b2 vaccine-associated myo/pericarditis in adolescents: a stratified risk-benefit analysis

Dengue after COVID-19 vaccination: possible and might be missed

Dengue and the heart

Myopericarditis and pericarditis in the deployed military member: a retrospective series

Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States

A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination

Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients

The incidence of cardiac complications in patients hospitalised with COVID-19 in Australia: the AUS-COVID study

Myocarditis with COVID-19 mRNA vaccines

Myocarditis and pericarditis following COVID-19 vaccination: inequalities in age and vaccine types

Surveillance for adverse events after COVID-19 mRNA vaccination

Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting